Special Educational Needs and Disabilities Review

Debate between Baroness Laing of Elderslie and Nadhim Zahawi

Tuesday 29th March 2022 Commons Chamber

[Nadhim Zahawi]

I certainly can. We are putting the best part of £5 billion into recovery.

[Madam Deputy Speaker (Dame Eleanor Laing)]

The prize for perseverance and patience goes to Holly Mumby-Croft.

[Holly Mumby-Croft (Scunthorpe) (Con)]

Thank you, Madam Deputy Speaker.

I recently visited St Hugh’s, an outstanding special school in my constituency. I was shown around by Thomas and Spencer, and I was incredibly impressed by both of them—they made a big impression on me. They are brilliant tour guides, and I hope to pay them back by giving them a tour of this place as soon as it can be arranged. Will my right hon. Friend the Secretary of State join me in thanking the staff and teachers at schools such as St Hugh’s for the brilliant work they are already doing, alongside the Government, to support our great young people like Thomas and Spencer?

[Nadhim Zahawi]

I certainly join my hon. Friend in thanking them. They go above and beyond. It has not been easy over the past couple of years, when they have had to deal with a global pandemic and, of course, deliver care and education for these children. I express my heartfelt thanks and gratitude for everything they do, and of course for everything this sector does across the country.

[Madam Deputy Speaker]

That concludes the statement. I thank the Secretary of State for answering so many questions so thoroughly.

Education: Return in January

Debate between Baroness Laing of Elderslie and Nadhim Zahawi

Wednesday 5th January 2022 Commons Chamber

[Nadhim Zahawi]

I am grateful to my hon. Friend for his incredibly important question. He cites the Milton Keynes feedback that he has received. Half a million children responded to the Children’s Commissioner’s Big Ask survey, including 2,500 children of Gypsy and Roma families and 16,000 children with special educational needs and disabilities. This generation is not a snowflake generation—it has been a pretty resilient generation through covid—but, actually, one thing the children cite very clearly is the impact on their mental health of schools not being open, and obviously being available only for the most vulnerable children and children of critical workers. I think that was a painful lesson for us to learn. I will never want to repeat that, and I will do everything in my power to keep schools open.

[Madam Deputy Speaker (Dame Eleanor Laing)]

Finally, I call Ben Bradley.

[Ben Bradley (Mansfield) (Con)]

Thank you, Madam Deputy Speaker. It is a shame to find myself bottom of the class, but I guess I must try harder.

I welcome the Secretary of State’s statement and his commitment to keeping schools open, which will be really important to parents in my constituency. It is not without its challenges, but given what we know about the lower heath risk to children and the emerging evidence about perhaps the less severe impact of the omicron variant, arguably the biggest challenge is staffing, which is why some of the measures he took over Christmas are so important.

I have two questions. First, could the Secretary of State tell my residents whether his scheme to promote people coming back into classrooms is still open, and if so, how can I encourage my constituents to sign up or where can I encourage them to sign up? Secondly, along with teachers, support staff are clearly hugely important—at Mansfield council, we have found shortages of cleaners and all sorts of other very important roles in schools—so has his Department considered what support or advice he might offer schools about those roles?

[Nadhim Zahawi]

My hon. Friend is certainly not bottom of the class. His experience of local government and his contribution to national Government are exemplary. That was a very good double question. On the first question, we have set up a dedicated site where people can register, inquire and come forward, and then be signposted to local agencies in their area to be able to sign up. On his second very good question, I am also looking at and monitoring support staff absenteeism because of the omicron virus, because they are equally important in making sure that our schools continue to remain open for face-to-face education.

[Madam Deputy Speaker]

Thank you. The House is very grateful to the Secretary of State. We now come to the next item of business—she said slowly, in order to allow a dignified exchange of personnel while keeping social distancing. I think we have achieved that now.

Covid-19 Vaccine Update

Debate between Baroness Laing of Elderslie and Nadhim Zahawi

Thursday 4th February 2021 Commons Chamber

[The Parliamentary Under-Secretary of State for Health and Social Care (Nadhim Zahawi)]

With permission, I would like to make a statement on coronavirus, but before I do that I wish my shadow opposite number, the hon. Member for Nottingham North (Alex Norris), a happy birthday.

Our nation is getting safer every day as more and more people get protected by the biggest immunisation programme in the history of our health service. More than 10 million people have now received their first dose of one of our coronavirus vaccines. That is almost one in five adults in the United Kingdom. We are vaccinating at scale, while at the same time retaining a close focus on the most vulnerable in our society to make sure those at greater need are at the front of the queue.

I am pleased to inform the House that in the UK we have now vaccinated almost nine in 10 over-80s, almost nine in 10 over-75s and more than half of people in their 70s. We have also visited every eligible care home possible with older residents in England and offered vaccinations to all their residents and staff. That means we are currently on track to meet our target of offering a vaccine to the four most vulnerable groups by mid-February.

That is an incredible effort that has drawn on the hard work of so many, and I want to just take a moment to thank every single person who has made this happen: the hundreds of thousands of volunteers up and down the country, the scientists, our colleagues in the NHS—the GPs, the doctors, the nurses and the vaccinators—those in social care, the manufacturers, the local authorities, the armed forces, the civil servants who work night and day to make this deployment possible, and anyone else who has played a part in this hugely logistical endeavour. It really is a combination of the best of the United Kingdom. At our time of national need, you have given us a big boost in our fight against this deadly virus, which remains a big threat to us all.

There are still more than 32,000 covid patients in hospital, and the level of infection is still alarmingly high, so we must all stay vigilant and keep our resolve while we keep expanding our vaccination programme, so that we can get more people protected even more quickly. We have an ambitious plan to do that. We are boosting our supply of vaccines and our portfolio now stands at more than 400 million doses, some of which will be manufactured in the United Kingdom, and we are opening more vaccination sites, too. I am pleased to inform the House that 39 new sites have opened their doors this week, along with 62 more pharmacy-led sites. That includes a church in Worcester, Selhurst Park—the home of Crystal Palace football club—and a fire station in Basingstoke, supported by firefighters and support staff from Hampshire Fire and Rescue Service.

One of the greatest pleasures for me over the past few months has been seeing the wide range of vaccination sites that have been set up right in the heart of our local communities. Cinemas, mosques, food courts and so many other institutions have now been transformed into life-saving facilities, giving hope to people every day. Thanks to that rapid expansion, we have now established major national infrastructure. There are now 89 large vaccination centres and 194 sites run by high street pharmacies, along with 1,000 GP-led services and more than 250 hospital hubs. Today’s announcement will mean that even more people will live close to a major vaccination site, so we can make vaccinating the most vulnerable even quicker and even simpler.

We have always believed in the power of science and ingenuity to get us through this crisis, and I was pleased earlier this week to see compelling findings in The Lancet medical journal, reinforcing the effectiveness of our Oxford-AstraZeneca vaccine. It showed that the vaccine provides sustained protection of 76% during the 12-week interval between the first and second dose, and that the vaccine seems likely to reduce transmission to others by two thirds. That is really great news for us all, but we will not rest on our laurels.

No one is really safe until the whole world is safe. Our scientific pioneers will keep innovating, so that we can help the whole world in our collective fight against this virus. I saw how wonderful and powerful this ingenuity could be when I was one of thousands of volunteers who took part in the Novavax clinical trial, which published very promising results a few days ago. Today, I am pleased to announce another clinical trial—a world-first study that will help to cement the UK’s position as a global hub for vaccination research. This trial will look at whether different vaccines can be safely used for a two-dose regime in the future to support a more flexible programme of immunisation. I want to reinforce that this is a year-long study, and there are no current plans to change our existing vaccination programme, which will continue to use the same doses. But it will perform a vital role, helping the world to understand whether different vaccines can be safely used. Our scientists have played a pivotal part in our response to this deadly virus, and once again they are leading the way, helping us to learn more about this virus and how we should respond.

It has been heart-warming to see how excited so many people have been to get their vaccine and to see the work taking place in local communities to encourage people to come forward to get their jab. Hon. Members have an important role to play too. I was heartened to see colleagues from both sides of the House coming together to encourage take-up within minority ethnic communities through two joint videos posted on social media last week. As the video rightly says, “MPs don’t agree all the time, but on taking the vaccination, we do.” I could not agree more, and I am grateful to every single Member who has come forward to support this national effort. We want to make it as easy as possible for colleagues to do so. This week, we published a new resource for Members that provides more information on the vaccine roll-out and what colleagues can do to increase the take-up of the vaccine in their constituencies. That is an extremely valuable resource, and I urge all Members to take a look at it and think about what they can do in their constituencies.

Our vaccination programme is our way out of this pandemic. Even though the programme is accelerating rapidly and, as the chief medical officer said yesterday, we appear to be past the peak, this remains a deadly virus, and it will take time for the impact of vaccinations to be felt. So for now, we must all stand firm and keep following the steps that we know make a big difference until the science can make us safe. I commend this statement to the House.

[Madam Deputy Speaker (Dame Eleanor Laing)]

Happy birthday to the hon. Member for Nottingham North (Alex Norris).

--- Later in debate ---

[Nadhim Zahawi]

I am grateful to the hon. Lady for her question. We will do so in a couple of ways. First, once we have enough vaccine supply to be able to offer the vaccine to every adult in the United Kingdom—every eligible group from 1 to 9 and then phase 2—we will then look at our vaccine supply strategy. At the moment, we are nowhere near having enough supply to be able to make that offer. That has to be our priority. She mentions COVAX, but that is only part of the story for us in the United Kingdom. We have put about £450 million-plus into COVAX, but a total of £1.3 billion into the vaccine initiative of GAVI, the Vaccine Alliance. We are, I think, the largest donor, not only in money but per capita. We are making a big, big impact globally in both research and development, and vaccinations to low and middle-income countries.

[Madam Deputy Speaker (Dame Eleanor Laing)]

I appreciate that colleagues have complicated questions to ask the Minister and that the answers are therefore also complicated, but I must ask for a bit more speed now, because we have taken an hour. I should stop proceedings on this item of business, but I will not do so because I appreciate that there are important questions to be asked. I urge Members to go just a little faster.

--- Later in debate ---

[Nadhim Zahawi]

I am grateful for my hon. Friend’s excellent, thoughtful suggestion. I will certainly take that away and discuss it with the Minister responsible in the Department.

[Madam Deputy Speaker (Dame Eleanor Laing)]

Thank you. We have covered a lot of ground. I will now suspend the House for three minutes, so that the Chamber can be prepared for the next item of business.

Covid-19: Vaccinations

Debate between Baroness Laing of Elderslie and Nadhim Zahawi

Monday 11th January 2021 Commons Chamber

[Nadhim Zahawi]

I am grateful for the hon. Member’s backing and support. He asks a number of important questions, and I will attempt to answer them now. Suffice it to say that it would be sensible for us to recognise that test and trace now delivers 85% of those who are tested positive in terms of identifying their direct contacts and the indirect contacts at between 92% and 96%. Over 5 million people have been tested and isolated and are therefore not transmitting or spreading this virus, and 55 million people have been tested. That is a pretty major undertaking, with capacity now touching 770,000 and tests running at about 600,000 a day. From a standing start of about 2,000 a day back in March, that is a pretty remarkable achievement for NHS test and trace.

The hon. Gentleman asked about 24-hour provision. There are two priorities for the NHS, and we have looked really long and hard at this. Priority No. 1 is obviously to target very closely those four most vulnerable categories. Priority No. 2 is to try to get a vaccination to them as quickly as possible, which is about throughput. This is linked because if we were to go to a 24-hour regime, it would be much harder to target the vaccine at those four cohorts. Obviously, when we have limited vaccine volume, we do not want staff standing around waiting for people in centres that are open 24 hours. Also, many of those people are over 80, and we are going into care homes to vaccinate the residents of those homes. The decision to go from 8 to 8 was made because we want to ensure that there is an even spread and very close targeting.

That is linked to throughput—how many vaccinations can we get into people’s arms as quickly as possible? We do not want vaccines sitting in fridges or on shelves. That goes to the hon. Gentleman’s question on the 24 hours, but also the pharmacy question. All the 200 pharmacies that we are operationalising can do 1,000-plus vaccinations a week, so the focus in phase 1, certainly with the first four categories—and, I think, with the total nine categories—is very much on targeting and throughput. The 2,700 sites are the best way that we can target that. Obviously, primary care is very good at identifying those who are most vulnerable or over 80 and, of course, getting into care homes, hence why the NHS plan and the plan we have published today are very much based around those priorities.

As we enter phase 2, where we begin to want to vaccinate as many adults as quickly as possible, we want convenience of course. We want to be able to go into many more pharmacies, so people can walk to their local pharmacy, or GP, and get their jab, when we have limitless volumes of vaccines. We have clearly now got that optioned and it will come through in the weeks and months ahead. That is the reason for that. The hon. Gentleman is absolutely right: the limiting factor continues at this stage to be vaccine volumes. The NHS has built an infrastructure that can deploy the vaccine as quickly as possible, but it is vaccine volumes that will change. With any new manufacturing process, especially one where we are dealing with quite a complex process—it is a biological compound that we are producing—it tends to be lumpy at the start, but it very quickly stabilises and becomes much more even. We are beginning to see that, which is good news.

We are absolutely committed to making sure the health and social care workforce are vaccinated as quickly as possible, and of course we are committed to making sure the residents of care homes are vaccinated by the end of this month—January. I reaffirm that commitment to the hon. Gentleman.

I think the hon. Gentleman’s final question was on data. I am glad that he agrees that it is important, because the Prime Minister’s absolute instruction to us as a team is that we have to make sure we publish as much data as possible as quickly as possible, hence why we have moved to a rhythm of daily data and on the Thursday more detailed publication, which will have regional breakdowns. The NHS is committed as it builds up more data to publish more and more. The nation expects, and rightly wants to see, the speed and the targeting that we are delivering, but I am confident that the NHS has a solid plan. We have the volunteers and the Army—two great institutions of this country—delivering this campaign and with the support of Her Majesty’s Opposition I am sure we will do this.

[Madam Deputy Speaker (Dame Eleanor Laing)]

We now go to the Chairman of the Health and Social Care Committee, Jeremy Hunt.

--- Later in debate ---

[Nadhim Zahawi]

There is a lot to unpack there; let me try to take the points in reverse. We can guarantee that those who have had their Pfizer vaccine will get their booster within the prescribed period of up to 12 weeks. The hon. Lady asked about those who have had a second jab already. Information went out to primary care networks and hospital hubs, saying that those who have an appointment up to 4 January should be able to have their appointment honoured. Beyond that, they have been working very closely with the NHS England team centrally, which we have been supporting with resources and actually phoning to postpone those appointments further; hence why we have protected many more people.

It is worth reminding the House that for every 250 people from the most vulnerable cohorts that we protect, we save a life. For every 20 people in care homes that we vaccinate, we save a life. The focus is therefore now very much on care homes. We began with the Pfizer vaccine into care homes. Of course, last week—on 4 January—we started to roll out the AstraZeneca vaccine, which is much easier to administer into care homes, especially for the roving teams. It had to spend two days in hospitals before it was released to primary care networks, but the moment it was released, it went into care homes and now some areas in England. We have about 10,000 care homes where we have to vaccinate residents and, of course, those who look after them. Some have done their care homes already; others are beginning to do the same thing. All will be done by the end of the month.

The hon. Lady talked about people having to travel long distances. I mentioned in my opening statement about the strategy that there will be 2,700 vaccination sites. I think she may have been confused about the figure of 1,200, which is the number of primary care networks, hospital hubs and large vaccination centres, but there will be 2,700 vaccination sites. By the end of the month, no one will be more than 10 miles away from a vaccination site.

[Madam Deputy Speaker (Dame Eleanor Laing)]

I thank the Minister for being so assiduous in giving very thorough answers to the long and complicated series of questions that have already been put to him, but I must say to the House that we now have half an hour more for the rest of this statement, so I insist on having questions, not statements, from everyone. I specifically mention this to people who are coming in virtually, because they seem to lose a sense of timing when they are not here in the Chamber. A question means a question—just one question. I say to the Minister, who has been most assiduous, that where he has already given an answer to the question, I will not insist that he has to give the answer again because the person who is now asking it has not listened to his first answer.

--- Later in debate ---

[Nadhim Zahawi]

I commend the Israeli Government and health service for a stellar job in vaccinating their most vulnerable communities. We have a lot to learn from other countries, including the throughput—the speed at which they manage to vaccinate—which is something from which we can all learn so that we can improve our output. NHS England and the teams on the frontline have been doing a tremendous job and is worth us all thinking about that: we stand on the shoulders of real heroes.

[Madam Deputy Speaker (Dame Eleanor Laing)]

We are way over time, so I am going to take only four more questions and I would be grateful if they could be swift.

--- Later in debate ---

[Nadhim Zahawi]

It is not our capacity, but the manufacturers’; AstraZeneca produces the Oxford vaccine, and Pfizer-BioNTech produce their vaccine, and Moderna’s is now also approved and in process. There are a number of processes throughout the manufacturing process. When we go from the bulk vaccine into fill and finish, there is a period of time and a sterility test the vaccines have to go through. Then there is batch testing by both the manufacturer and the regulator. All of that gets better and better every single day. It is a new manufacturing process. Oxford-AstraZeneca are delivering 100 million vaccines, which is what we have bought from them, and we have bought 40 million from Pfizer. We will have millions of vaccines in the weeks and months to come. We will meet our target of mid February for delivering the opportunity of a vaccine to the four cohorts most vulnerable to covid.

[Madam Deputy Speaker (Dame Eleanor Laing)]

I thank the Minister. I am sorry to the nine colleagues who have not been called to ask their questions. I hope they will encourage their colleagues to ask shorter questions in future, because that is how we will manage to be fairer in getting more people in.

Pupil Referral Units

Debate between Baroness Laing of Elderslie and Nadhim Zahawi

Tuesday 22nd January 2019 Commons Chamber

[Nadhim Zahawi]

I am grateful to the hon. Lady for coming back on that point, which I was about to address. Local authorities can make arrangements for the supply of specialist support for mainstream schools by staff working in pupil referral units. The Department’s innovation fund has funded projects that include such measures and links between AP and schools. If she is unhappy with my response, and if she writes to me about a specific case, I will be happy to look at that as well.

I thank the hon. Member for Lewisham, Deptford (Vicky Foxcroft), my hon. Friend the Member for Bolton West and the hon. Member for Strangford, who is no longer in his seat, for contributing to this debate. I also pay tribute to the hard work of schools and local authorities, which continue to give their best and to raise the standards of our education system.

[Madam Deputy Speaker (Dame Eleanor Laing)]

Order. Before I put the Question, I must inform the House that there was an error in calculating the number of votes of Members for English constituencies in the Division on motion 7 on the Higher Education (Fee Limits for Accelerated Courses) (England) Regulations 2018. The figures for the England-only vote should not have been announced as: Ayes, 269; Noes, 200. They should have been announced as: Ayes, 269; Noes, 194. The figures for the vote of the whole House are as previously announced, and the result is unaffected.

I appreciate the attention of the House. It is not an exciting announcement, but it is essential to set the record straight.

Question put and agreed to.